Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Buflomedil

A vasoactive drug authorised in Europe from the 1970s for intermittent claudication, the leg pain on walking caused by peripheral arterial disease; in 2011 the European Medicines Agency recommended its suspension throughout the EU. This family brings together the active ingredient, pharmacopoeial impurities and other impurities.

Did you know?It worked on several fronts at once: it blocked alpha receptors in blood vessels, reduced platelet aggregation and made red blood cells more deformable, so that they could pass more easily through capillaries.

BuflomedilGo to the active ingredient →
BuflomedilActive ingredientBuflomedilCat. No. P-B133-001CAS 55837-25-7

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.